Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

Leendert H Zaaijer; Helena C van Doorn; Marian J E Mourits; Marc van Beurden; Joanne A de Hullu; Muriel A Adank; Luc R C W van Lonkhuijzen; Hans F A Vasen; Brigitte F M Slangen; Katja N Gaarenstroom; Ronald P Zweemer; Peggy M L H Vencken; Caroline Seynaeve; Mieke Kriege

doi:10.1038/bjc.2016.333

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

Br J Cancer. 2016 Nov 8;115(10):1174-1178. doi: 10.1038/bjc.2016.333. Epub 2016 Oct 18.

Authors

Affiliations

¹ Department of Obstetrics and Gynaecology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
² Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
³ Department of Obstetrics and Gynaecology, Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
⁴ Department of Obstetrics and Gynaecology, Netherlands Cancer Institute NKI-AVL, Amsterdam, The Netherlands.
⁵ Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
⁶ Department of Clinical Genetics, VU Medical Centre, Amsterdam, The Netherlands.
⁷ Center for Gynecologic Oncology, Academic Medical Centre, Amsterdam, The Netherlands.
⁸ Foundation for the Detection of Hereditary Tumours (STOET), Leiden, The Netherlands.
⁹ Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
¹⁰ Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands.
¹¹ Department Gynaecological Oncology, UMC Utrecht Cancer Centre, Utrecht, The Netherlands.
¹² Department of Obstetrics and Gynaecology, Bravis Hospital, Bergen op Zoom, The Netherlands.

Abstract

Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis.

Methods: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC.

Results: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HR_mult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HR_mult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HR_mult 1.15; 95% CI 0.84-1.57) and OCSS (HR_mult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HR_mult 1.99; 95% CI 1.21-3.31).

Conclusions: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.

MeSH terms

Adult
Aged
Aged, 80 and over
BRCA1 Protein / genetics*
BRCA2 Protein / genetics*
Breast Neoplasms / genetics*
Breast Neoplasms / mortality*
Carcinoma, Ovarian Epithelial
Disease-Free Survival
Female
Humans
Middle Aged
Mutation / genetics*
Neoplasms, Glandular and Epithelial / genetics
Ovarian Neoplasms / genetics*
Ovarian Neoplasms / mortality*
Prognosis
Young Adult

Substances

BRCA1 Protein
BRCA1 protein, human
BRCA2 Protein
BRCA2 protein, human